Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" google.com

Incidence and risk factors for graft failure after allogeneic hematopoietic stem cell ...

google.com·25w

Merck to present new data across multiple hematologic malignancies at ASH Annual ...

google.com·25w

The subscription period in Active Biotech's rights issue begins today - TradingView

google.com·25w

ASH 2025 preview – a new menin battleground | ApexOnco - Oncology Pipeline

google.com·25w

SANRECO Trial Explores Divesiran for <b>Polycythemia Vera</b> Treatment - CUREtoday.com

google.com·25w

Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued ...

google.com·25w

European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for <b>myelofibrosis</b>

google.com·25w

Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued ...

google.com·25w

PharmaEssentia Announces Publication of Phase 3 SURPASS-ET Results in The Lancet ...

google.com·25w

MERCK to present hematology pipeline data at ASH 2025 meeting - StreetInsider

google.com·25w

Combinatorial BCL2/BCL2L1 expression predicts clinical response to ruxolitinib in <b>myelofibrosis</b>

google.com·25w

Active Biotech Publishes Preclinical Data on Tasquinimod in <b>Myelofibrosis</b> - MarketScreener

google.com·25w

Active Biotech&#39;s Tasquinimod Shows Promise in <b>Myelofibrosis</b> Treatment - TipRanks.com

google.com·25w

Positive preclinical tasquinimod data in <b>myelofibrosis</b> published in Blood Advances

google.com·25w

Drivers of Endothelial Inflammation in MF Identified - Hematology Advisor

google.com·40w

Syntara receives FDA guidance for amsulostat in <b>myelofibrosis</b> treatment - Biotech

google.com·40w

Syntara&#39;s stock plunges 52% following FDA request for added trial | BioWorld

google.com·40w

<b>Myelofibrosis</b> Trials: Diverging Narratives on Enrollment, Endpoint Clarity, and Safety Data

google.com·40w

Karyopharm Therapeutics Sees $1B Peak Revenue Potential in <b>Myelofibrosis</b> by 2026

google.com·40w

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent ...

google.com·40w

Log in to enable infinite scrolling